

Angiotensin-2 predicts morbidity in adults with Fontan physiology

Aditya S. Shirali ^{a‡}, Gentian Lluri ^{b‡*}, Pierre J. Guihard ^c, Miles B. Conrad ^d, Helen Kim ^{e,f},
Ludmila Pawlikowska ^{e,f}, Kristina I. Boström ^c, M. Luisa Iruela-Arispe ^g, Jamil A. Aboulhosn ^{b*}

^a Department of Surgery, University of California Los Angeles, Los Angeles, CA

^b Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Cardiology, University of California Los Angeles, Los Angeles, CA

^c Division of Cardiology, University of California Los Angeles, Los Angeles, CA


^d Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA

^e Center for Cerebrovascular Research, Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, CA

^f Institute for Human Genetics, University of California San Francisco, San Francisco, CA

^g Department of Molecular, Cell & Developmental Biology, Molecular Biology Institute and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA

‡ These authors contributed equally to this work.



Supplementary Figure 1. A. Plasma angiotensin-converting enzyme 2 levels in patients with (red) and without (clear) ascites, history of arrhythmia and active or recent (within 6 months) arrhythmia. There is a significant difference in angiotensin-converting enzyme 2 in Fontan patients with active or recent arrhythmia ($p < 0.05$). B. The percent of Fontan patients with active arrhythmia or recent arrhythmia (within 6 months) with angiotensin-converting enzyme 2 levels greater than 8,500 pg/mL ($n=5/12$) and less than 8,500 pg/mL ($n=0/13$). A significant difference exists between these groups ($p < 0.05$)